van Loevezijn, Ariane A.
van der Noordaa, Marieke E. M.
Stokkel, Marcel P. M.
van Werkhoven, Erik D.
Groen, Emma J.
Loo, Claudette E.
Elkhuizen, Paula H. M.
Sonke, Gabe S.
Russell, Nicola S.
van Duijnhoven, Frederieke H.
Vrancken Peeters, Marie-Jeanne T. F. D.
Article History
Received: 8 January 2022
Accepted: 13 February 2022
First Online: 3 March 2022
Declarations
:
: GS received institutional research support from AstraZeneca, Merck, Novartis, and Roche outside the scope of this manuscript. All other authors declare no competing interests.
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The institutional review board of the Netherlands Cancer Institute approved this study.
: This study was conducted retrospectively from data obtained for clinical purposes. An official waiver of ethical approval was granted from the institutional review board.
: The datasets generated for the current study are available from the corresponding author on reasonable request.